Advancing the CMC Development of Oncology Medicines
We are dedicated to accelerating the development of new drugs for patients around the world. We provide CRO and CDMO services including formulation development, clinical pharmacology trials, and clinical and commercial manufacturing services to the pharmaceutical and biotech industry. These services are provided either individually or as an integrated service offering via our Translational Pharmaceutics® platform.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Quotient is your answer.
Our latest updates
News
Quotient and ANA Therapeutics announce partnership to develop drug candidate, ANA001 (niclosamide capsules) as a potential treatment for COVID-19.
Exhibition
Schedule a 1:1 partnering meeting with our CSO, Dr Peter Scholes at the virtual Biotech Showcase 2021 event.
Webinar
This webinar discusses effective strategies being used by biotech and pharmaceutical companies to overcome biopharmaceutic challenges for small molecules in today’s drug development pipeline; and explores alternative approaches for accelerating your early development plan.
News
A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials announced by Quotient Sciences and CytoAgents.
Ask us a question
